Six years sep­a­rat­ed from a ra­bies vac­cine scan­dal, Chi­na’s Yisheng­Bio grabs $130M to go big in in­fec­tious dis­eases, can­cer

In an­oth­er boost to the glob­al vac­cine field, top in­vestors in Chi­na have hud­dled to­geth­er to in­ject $130 mil­lion in­to Bei­jing-based Yisheng­Bio.

Co-led by Ocean­pine and Or­biMed, the Se­ries B now gives the biotech an en­vi­able list of mar­quee do­mes­tic VCs: EightRoad, F-Prime Cap­i­tal, 3W Cap­i­tal, Hill­house Cap­i­tal, MSA Cap­i­tal, AI­HC, Epiphron Cap­i­tal, Su­per­string Cap­i­tal and Haitong In­ter­na­tion­al. The stand­out here is Ad­ju­vant Cap­i­tal, a pub­lic-health-mind­ed crew with ties to the Gates Foun­da­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.